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All of us cardiologists have been asked about vaccination 
against yellow fever during consultations, as well as in 
phone calls or messages from patients or family members. 
The reason is that the outbreak of the disease has appeared 
on the news daily causing the whole country to worry.
Even in the absence of a consensus on universal vac-
cination, the current epidemiological situation requires 
the intensification of measures in the short term due to 
the risk of triggering a catastrophic urban epidemic with 
high morbidity and mortality. 
One of the most difficult decisions involving medical 
liability is in the recommendation for patients over the 
age of 60 years, when there is a higher incidence of adverse 
events that, although rare, can be serious and fatal. 
These complications have been reported in studies 
with the non-fractional vaccine on a regular basis and we 
do not know if they would be even rarer with the fraction-
al vaccine that is now being used.
It must be understood that this situation is dynamic, 
like any epidemic or pandemic outbreak, and there is a 
permanent need for reassessment, clarification and guidance. 
Thus, public health authorities and medical societies have 
advised that patients over 60 years should consult their 
professional for advice, which requires careful evaluation 
of the epidemiological risk. It is physician’s responsibility 
to define the protection of this age group in the population. 
If they are not vaccinated and become infected, they can 
rapidly progress to severe forms that will increase the com-
plications of any underlying conditions. The decision in-
volves comparing the risk of developing complications, 
estimated for the elderly (with the entire vaccine) at 1 per 
100,000 (60 to 70 years-old) or 1 per 30,000 (> 70 years-old) 
versus 1-2 per 1 million in non-elderly individuals.
Therefore, the Ministry of Health published a gener-
ic guide:
Ministry of health – Guide to vaccination 
criteria aGainst yellow fever
Precautions
Thorough and individualized risk and benefit assessment 
for vaccine recommendation is required as follows: 
 • Acute moderate or severe febrile conditions.
 • First yellow fever vaccination in people aged 60 and over.
 • Blood or organ donors.
 • HIV-infected individuals, asymptomatic and with 
moderate immunosuppression according to CD4 
count.
 • People with potentially autoimmune diseases.
 • People with hematological diseases.
 • Patients who have developed demyelinating neuro-
logical disease within 6 weeks after the previous dose 
of the vaccine.
 • Pregnant and breastfeeding women.
Contraindications
 • Children under 6 months of age.
 • Individuals with a history of severe adverse events 
with previous doses.
 • Those with a history of laboratory-proven anaphyla-
xis with previous doses or anaphylaxis related to the 
substances present in the vaccine (chicken egg and 
its derivatives, bovine gelatine or others).
 • Patients with severe immunosuppression of any nature.
 • Patients undergoing organ transplantation.
 • Patients with previous history of thymus disease.
 • Patients with systemic lupus erythematosus.
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However, some special situations in cardiological 
patients can cause doubt. 
We list some of them below, which can make it easier 
for us to guide patients:
1. I am over 60 years and am going to travel to an area with 
a high incidence of yellow fever; should I be vaccinated? 
If you are over 60 years old, but do not meet the contra-
indication criteria, vaccination is recommended, even if 
you have a chronic disease such as heart failure (HF), di-
abetes mellitus (DM) or coronary artery disease (CAD). 
If you have any of the contraindications, you should not 
travel or, if it is unavoidable, use insect repellent and avoid 
exposing yourself.
2. I am over 60 years, I live in an urban area with a low 
incidence of the disease and I will not travel to any 
endemic area, should I be vaccinated? 
In this case, the risk of vaccination is greater than the benefit.
3. Can a patient aged less than 60 years but with a 
chronic disease (such as HF, DM or CAD) be vaccinated? 
Yes, and should be. The simple presence of chronic disease 
does not contraindicate vaccination.
4. My patient is young and has a complex congenital 
heart disease. Can he be vaccinated? 
Yes, he can. Patients with congenital heart diseases, even 
complex ones, and aged over 6 months can be vaccinated. 
5. My patient has valvulopathy with a history of rheu-
matic fever (which is ultimately an autoimmune disease) 
but has not had activity. Should he be vaccinated? 
There is nothing specific for rheumatic fever and all pa-
tients with controlled autoimmune diseases, in the ab-
sence of immunosuppression, may theoretically receive 
the vaccine except for lupus, which is a contraindication. 
In this case, there are still controversies. 
6. Does vaccination against yellow fever cause myocarditis?
Yellow fever virus infection is one of the causes of myo-
carditis; post-vaccinal myocarditis alone is possible but 
extremely rare.
7. My patient had myocarditis with no defined etiology. 
Can he be vaccinated?
Yes, he can. Vaccination is not contraindicated, whether 
the ventricular function has been recovered or not.
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